Alliancebernstein L.P. Adverum Biotechnologies, Inc. Transaction History

Alliancebernstein L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $82,701 - $136,814	-102,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.23 - $1.95 $492 - $780	400 Added 0.39%	102,100 $134,000
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $18,444 - $25,440	-10,600 Reduced 9.44%	101,700 $179,000
Q3 2021 Nov 10, 2021	SELL	$2.08 - $3.6 $23,296 - $40,320	-11,200 Reduced 9.07%	112,300 $244,000
Q2 2021 Jul 30, 2021	BUY	$3.36 - $10.56 $77,952 - $244,992	23,200 Added 23.13%	123,500 $432,000
Q3 2020 Nov 12, 2020	SELL	$10.3 - $21.64 $21,630 - $45,444	-2,100 Reduced 2.05%	100,300 $1.03 Million
Q2 2020 Aug 13, 2020	BUY	$8.53 - $25.64 $311,345 - $935,860	36,500 Added 55.39%	102,400 $2.14 Million
Q1 2020 May 14, 2020	BUY	$7.98 - $16.32 $94,164 - $192,576	11,800 Added 21.81%	65,900 $644,000
Q2 2019 Aug 14, 2019	BUY	$5.1 - $11.89 $172,380 - $401,882	33,800 Added 166.5%	54,100 $643,000
Q1 2019 May 14, 2019	BUY	$3.03 - $6.02 $9,393 - $18,662	3,100 Added 18.02%	20,300 $106,000
Q3 2018 Nov 08, 2018	BUY	$4.5 - $7.6 $28,800 - $48,640	6,400 Added 59.26%	17,200 $104,000
Q2 2018 Aug 13, 2018	BUY	$5.3 - $6.9 $57,240 - $74,520	10,800 New	10,800 $57,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.